Table 2 Summary of major psychological and physical adverse effects associated with non-medical testosterone and anabolicandrogenic steroid use
A 2025 analysis by the Employers Health Coalition found that 64% of large employers (5,000+ employees) excluded GLP-1 medications for obesity from their health plans, citing projected costs of $12,000 to $15,000 per patient per year (Jain et al., Health Affairs 2025)
The GLP-1 Market: Key Players, Size, Pipeline and Projected Growth The GLP-1 agonist market is now a headline global market within pharmaceuticals
Thats a quality control issue, not a glutathione issue
Everything seems to be working perfectly until it suddenly isnt
Intriguingly, lysosomal and autophagy flux inhibitor Baf-A1 showed similar rescuing effect as DFO